• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB.

作者信息

Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict W F, Prager D

机构信息

Department of Medicine, Cedars-Sinai Research Institute-University of California Los Angeles School of Medicine 90048, USA.

出版信息

Cancer Res. 1995 Apr 15;55(8):1613-6.

PMID:7712461
Abstract

Mice bearing retinoblastoma susceptibility gene (RB) germ-line mutations almost invariably develop pituitary neoplasms. We therefore tested 17 patients with pituitary tumors for loss of heterozygosity (LOH) using an RB sequence polymorphism and 5 polymorphic microsatellite markers surrounding the RB gene on the long arm of chromosome 13. In all of the 13 malignant or highly invasive pituitary tumor cases, and in 4 of their respective metastases, a RB allele was lost. In contrast, no LOH at the RB locus was detected in 4 benign pituitary adenoma cases. Three invasive tumors also lost a portion of 13q, which included D13s137, D13s133, and D13s118 telomeric and centromeric to RB, respectively. Immunohistochemical analysis, however, revealed the presence of RB protein in tumors with LOH and the RB locus. Therefore, although inactivation of RB may play a role in the development of invasive pituitary adenomas and carcinomas in mice, another tumor suppressor gene on 13q is likely involved in human pituitary tumor progression. LOH of 13q markers may also be of predictive value in determining the biological behavior of pituitary macroadenomas and their progression to invasiveness and frank malignancy.

摘要

相似文献

1
Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB.
Cancer Res. 1995 Apr 15;55(8):1613-6.
2
Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma.人类肝细胞癌中13号染色体长臂缺失、视网膜母细胞瘤1基因突变及视网膜母细胞瘤蛋白状态
Cancer Res. 1994 Aug 1;54(15):4177-82.
3
Infrequent inactivation of the retinoblastoma gene despite frequent loss of chromosome 13q in head and neck squamous cell carcinoma.尽管在头颈部鳞状细胞癌中13号染色体长臂频繁缺失,但视网膜母细胞瘤基因的失活并不常见。
Cancer Res. 1994 Sep 1;54(17):4603-6.
4
Chromosome 13q deletion mapping in pituitary tumors: infrequent loss of the retinoblastoma susceptibility gene (RB1) locus despite loss of RB1 protein product in somatotrophinomas.垂体肿瘤中13号染色体长臂缺失图谱:尽管生长激素瘤中视网膜母细胞瘤易感基因(RB1)蛋白产物缺失,但RB1基因座缺失并不常见。
Cancer Res. 1999 Apr 1;59(7):1562-6.
5
Deletion of three distinct regions on chromosome 13q in human non-small-cell lung cancer.人类非小细胞肺癌中13号染色体长臂上三个不同区域的缺失。
Int J Cancer. 1997 Feb 20;74(1):45-9. doi: 10.1002/(sici)1097-0215(19970220)74:1<45::aid-ijc8>3.0.co;2-0.
6
Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours.
Clin Endocrinol (Oxf). 1996 Aug;45(2):195-200. doi: 10.1046/j.1365-2265.1996.d01-1561.x.
7
The retinoblastoma gene is involved in malignant progression of astrocytomas.视网膜母细胞瘤基因与星形细胞瘤的恶性进展有关。
Ann Neurol. 1994 Nov;36(5):714-21. doi: 10.1002/ana.410360505.
8
Human pituitary adenomas show no loss of heterozygosity at the retinoblastoma gene locus.人类垂体腺瘤在视网膜母细胞瘤基因位点未显示杂合性缺失。
J Clin Endocrinol Metab. 1994 Apr;78(4):922-7. doi: 10.1210/jcem.78.4.8157722.
9
Evidence for the presence of two tumour-suppressor genes for hepatocellular carcinoma on chromosome 13q.13号染色体长臂上存在两个肝细胞癌肿瘤抑制基因的证据。
Br J Cancer. 1995 Aug;72(2):383-5. doi: 10.1038/bjc.1995.342.
10
Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker.垂体腺瘤中的等位基因缺失反映了侵袭性生物学活性,并且作为一种预后标志物具有潜在价值。
J Clin Endocrinol Metab. 1997 Mar;82(3):818-24. doi: 10.1210/jcem.82.3.3799.

引用本文的文献

1
MiR-326: Role and significance in brain cancers.微小RNA-326:在脑癌中的作用及意义
Noncoding RNA Res. 2025 Feb 25;12:56-64. doi: 10.1016/j.ncrna.2025.02.006. eCollection 2025 Jun.
2
The 2022 WHO classification of tumors of the pituitary gland: An update on aggressive and metastatic pituitary neuroendocrine tumors.《2022年世界卫生组织垂体肿瘤分类:侵袭性和转移性垂体神经内分泌肿瘤的最新进展》
Brain Pathol. 2025 Jan;35(1):e13302. doi: 10.1111/bpa.13302. Epub 2024 Sep 1.
3
Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas.
帕唑帕尼的治疗反应:泌乳素瘤侵袭性的分子异常的病例报告及文献复习。
Front Endocrinol (Lausanne). 2023 Jul 17;14:1195792. doi: 10.3389/fendo.2023.1195792. eCollection 2023.
4
Asian-specific 3'UTR variant in CDKN2B associated with risk of pituitary adenoma.亚洲特有的 CDKN2B 3'UTR 变异与垂体腺瘤风险相关。
Mol Biol Rep. 2022 Nov;49(11):10339-10346. doi: 10.1007/s11033-022-07796-1. Epub 2022 Sep 12.
5
Clinical Biology of the Pituitary Adenoma.垂体腺瘤的临床生物学。
Endocr Rev. 2022 Nov 25;43(6):1003-1037. doi: 10.1210/endrev/bnac010.
6
Recent Understanding and Future Directions of Recurrent Corticotroph Tumors.复发性促肾上腺皮质细胞瘤的最新认识与未来方向。
Front Endocrinol (Lausanne). 2021 Apr 26;12:657382. doi: 10.3389/fendo.2021.657382. eCollection 2021.
7
Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?垂体瘤的基因组学和表观基因组学:病理学家需要了解什么?
Endocr Pathol. 2021 Mar;32(1):3-16. doi: 10.1007/s12022-021-09663-4. Epub 2021 Jan 12.
8
National trends in hospital readmission following transsphenoidal surgery for pituitary lesions.全国范围内经蝶窦手术治疗垂体病变后的医院再入院趋势。
Pituitary. 2020 Apr;23(2):79-91. doi: 10.1007/s11102-019-01007-0.
9
miR-15a/miR-16-1 expression inversely correlates with cyclin D1 levels in Men1 pituitary NETs.在多发性内分泌腺瘤1型垂体神经内分泌肿瘤中,miR-15a/miR-16-1的表达与细胞周期蛋白D1水平呈负相关。
J Endocrinol. 2019 Jan;240(1):41-50. doi: 10.1530/JOE-18-0278.
10
Cell Cycle Regulators and Lineage-Specific Therapeutic Targets for Cushing Disease.库欣病的细胞周期调节因子和谱系特异性治疗靶点
Front Endocrinol (Lausanne). 2018 Aug 10;9:444. doi: 10.3389/fendo.2018.00444. eCollection 2018.